Global Artificial Intelligence (AI) In Pharmaceutical Market Size and Trends

Global artificial intelligence (AI) in pharmaceutical market is estimated to be valued at USD 1,108.1 Mn in 2024 and is expected to reach USD 7,776.2 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 32.1% from 2024 to 2031.

Global Artificial Intelligence (AI) In Pharmaceutical Market Key Factors

To learn more about this report, request sample copy

The market is witnessing growth due to rising investment by key pharmaceutical players in AI technologies. AI help pharmaceutical companies in accelerating drug discovery process and precision medicine. Machine learning and deep learning algorithms also aid in analysis of large healthcare and clinical datasets for better understanding of diseases. Furthermore, rising chronic diseases due to changing lifestyle and increasing focus on developing targeted therapies can boosts demand for AI in pharmaceutical industry. Personalization of treatment based on patients' genetic makeup using AI can offer new opportunities for the market players in the near future.

Accelerating Drug Discovery Timeline with AI

The pharmaceutical industry has always been under immense pressure to bring new drugs to the market at a faster pace to cater to growing needs of patients worldwide. However, traditional drug discovery methods, which rely solely on human intellect and experimentation, have proven inefficient to keep up with this demand. Shifting through petabytes of scientific literature and clinical data to identify new drug targets and designing novel molecules often takes years of laborious research. Thus, AI plays a transformational role by augmenting human capabilities with its advanced computational powers and ability to analyze massive volumes of unstructured data. Machine learning and deep learning algorithms are being used to perform in-silico screening of millions of potential drug candidates against known drug targets within hours. Natural language processing models analyze literature to find associations and extract never explored insights, saving significant time spent on manual data scrutiny. AI tools are also assisting in hit-to-lead optimization processes by accurately predicting drug properties and side effects at early stages itself. Pharmaceutical giants have started leveraging these capabilities offered by AI. For example, Bayer partnered with an AI startup to apply machine learning on protein structures for speeding up drug discovery against cancer and cardiovascular diseases. Pfizer collaborated with IBM's Watson to enhance its R&D productivity using cognitive computing. Such strategic AI integrations are demonstrating the potential to slash years off traditional discovery timelines. If this trend continues, AI could become fully embedded in pharma workflows to accelerate every step from target identification to clinical trials.

Advancements in Specialized Biologics and Targeted Therapies

Rising investments in artificial intelligence by pharmaceutical companies can drive the artificial intelligence (AI) in pharmaceutical market growth. Pharmaceutical giants are increasingly leveraging AI systems to accelerate drug discovery processes and make them more efficient. AI has the potential to analyze huge tranches of medical data more quickly and uncover novel insights that humans may miss. This helps pharmaceutical companies reduce drug discovery costs and time as AI supplements human efforts. For example, many top pharmaceutical companies like Pfizer, Merck, GSK and AstraZeneca have ramped up their AI investments in recent years. As per the data published by the United Nations World Intellectual Property Organization in 2022, pharma patent filings related to AI had increased by over 30% between 2020 to 2021 due to applications in precision medicine and clinical trials. Drug makers are utilizing AI for tasks like analyzing genetic data to develop personalized treatments, improving clinical trial recruitment and monitoring drug safety. AI algorithms can also predict potential side effects of new molecules early in the drug discovery process from huge chemical and biological databases which often saves millions of dollars and years of research if red flagged early. The applications of AI are projected to transform drug discovery, disease screening, treatment recommendation and remote patient monitoring in the next 5 years, according to a 2021 report by World Health Organization. This will likely accelerate the discovery of new cures and boost treatment effectiveness. AI also poses important challenges around data privacy, bias and regulatory compliance that needs careful consideration for realizing its full benefits. Rising investments in this transformational technology can offer immense opportunities for innovation and efficiency gains in pharmaceutical industry with implications for better health outcomes around the world.